Clinical trials: Chronic Rhinosinusitis, Polyps
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP), Asthma
ReAl-woRld Evaluation of tEzepelumab for Chronic rhinoSinusitis With Nasal Polyps in Russia
ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated…
- Trial name
- ARES (NCT07399665)
- Where
- 10 sites in Russia
- Volunteers
- 110 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis
Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps
This is a multicenter, randomized, continuing, Phase II expansion trial to evaluate the safety, efficacy, and immunogenicity of two doses of TQH2722 in the long-term treatment of severe chronic sinusitis with or without nasal…
- Trial name
- NCT06439381
- Testing
- 300mg/600mg of TQH2722 injection
- Where
- 27 sites in China
- Volunteers
- 119 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyposis
Study in Adults With Severe Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab in France
This is a multicentre, non-interventional, single arm study that aims to describe the treatment patterns in France: patients' characteristics, disease characteristics, prior treatments for Severe chronic rhinosinusitis with nasal…
- Trial name
- OPALE (NCT06393946)
- Testing
- Dupilumab
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Sanofi
Chronic Rhinosinusitis With Nasal Polyps
A Study of GR1802 in Participants With Chronic Sinusitis With Nasal Polyps
The goal of this clinical trial is to learn if GR1802 works to treat severe chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. It will also learn about the safety of GR1802. The main questions it aims to answer are: 1.
- Trial name
- NCT06516302
- Testing
- GR1802
- Where
- China
- Volunteers
- 228 people
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps
A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis…
- Trial name
- DUBHE (NCT05324137)
- Testing
- CM326
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyps
Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps
The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP)
- Trial name
- NCT07132827
- Testing
- SHR-1905 Injection
- Where
- China
- Volunteers
- 280 people
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Nasal Polyps, Chronic Rhinosinusitis
A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps
The purpose of this study is to determine the efficacy and safety of omalizumab compared with placebo in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who have had an inadequate response to…
- Trial name
- POLYP 2 (NCT03280537)
- Testing
- Omalizumab
- Where
- 45 sites in United States, Belgium and 8 more
- Volunteers
- 127 people
- Sponsor
- Hoffmann-La Roche
Chronic Rhinosinusitis Without Nasal Polyps
Efficacy and Safety of 186 mcg of OPN-375 Nasal Spray Twice a Day (BID) in Adolescents With Chronic Rhinosinusitis Without Nasal Polyps
This is a 12-Week randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of intranasal administration of 186 µg of OPN-375 twice a day (BID) in adolescent subjects with…
- Trial name
- Re-Open 3 (NCT06850805)
- Testing
- OPN-375
- Where
- 24 sites in United States
- Volunteers
- 84 people
- Sponsor
- Optinose US Inc.
Chronic Sinusitis
Safety and Performance of the Steroid-Releasing S8 Sinus Implant
The purpose of this study was to assess the safety and performance of the steroid-releasing S8 Sinus Implant when used in post-sinus surgery patients who presented with recurrent sinus obstruction.
- Trial name
- S8PK (NCT01894503)
- Testing
- S8 Sinus Implant (mometasone furoate, 1350 mcg)
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Intersect ENT
Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis
Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)
This is a randomized, double-blind, placebo-controlled, parallel-group, international, multicenter, Phase 3 study to evaluate the efficacy and safety of repeat dosing of benralizumab 30 mg administered subcutaneously (SC) versus…
- Trial name
- ORCHID (NCT04157335)
- Testing
- Benralizumab 30 mg
- Where
- 116 sites in United States, Argentina and 15 more
- Volunteers
- 295 people
- Sponsor
- AstraZeneca
Nasal Polyps
A Study to Assess the Efficacy and Safety of GSK5784283 (Felcorekibart) in Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
The aim of this study is to assess the efficacy and safety of GSK5784283 administered as add-on maintenance therapy to participants with CRSwNP.
- Trial name
- PERSISTCRSwNP1 (NCT07782970)
- Testing
- GSK5784283, Standard of Care
- Where
- 8 sites in United States, Japan and 1 more
- Volunteers
- 218 people
- Sponsor
- GlaxoSmithKline
Chronic Rhinosinusitis With Nasal Polyps
Study to Evaluate Safety and Activity of TRL1068 in Chronic Rhinosinusitis
TRL1068 is expected to eliminate the pathogen-protecting biofilm in Chronic Rhinosinusitis, thus making these bacteria substantially more susceptible to established antibiotic treatment regimens.
- Trial name
- NCT05355207
- Testing
- TRL1068
- Volunteers
- 12 people
- Sponsor
- Trellis Bioscience LLC
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
PETRICHOR is a prospective, non-interventional, single-arm, multi-centre study in Germany evaluating real-world clinical and patient-reported outcomes in adults with severe chronic rhinosinusitis with nasal polyps (CRSwNP), whose…
- Trial name
- PETRICHOR (NCT07633158)
- Where
- 19 sites in Germany
- Volunteers
- 200 people
- Sponsor
- AstraZeneca
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
EFC18419 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups.
- Trial name
- CEREN-2 (NCT06834360)
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 111 sites in United States, Argentina and 21 more
- Volunteers
- 216 people
- Sponsor
- Sanofi
Sinusitis
A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps.
To evaluate the effectiveness, safety and pharmacokinetics of TQH2722 injection in patients with chronic sinusitis with or without nasal polyps.
- Trial name
- NCT06089278
- Testing
- 300mg of TQH2722 injection, 600mg of TQH2722 injection
- Where
- 36 sites in China
- Volunteers
- 160 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
This is a randomized, multicenter, double-blind, Phase 3 study with 2 parallel groups. The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different dosing regimens of itepekimab monotherapy in…
- Trial name
- CEREN-4 (NCT07484230)
- Testing
- Itepekimab (SAR440340)
- Sponsor
- Sanofi
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
The purpose of this study is to compare the efficacy and safety of rimegepant versus placebo in the acute treatment of chronic rhinosinusitis (CRS) with and without nasal polyps.
- Trial name
- NCT05248997
- Testing
- rimegepant 75 mg ODT
- Where
- 33 sites in United States
- Volunteers
- 261 people
- Sponsor
- Pfizer
Chronic Rhinosinusitis Without Nasal Polyps
A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)
The primary purpose of the study is to evaluate the efficacy of brensocatib at 10 and 40 milligrams (mg) once daily (QD) compared with placebo in improving clinical symptoms of CRSsNP.
- Trial name
- BiRCh (NCT06013241)
- Testing
- Brensocatib, Mometasone furoate nasal spray (MFNS)
- Where
- 100 sites in United States, Argentina and 13 more
- Volunteers
- 288 people
- Sponsor
- Insmed Incorporated
Chronic Rhinosinusitis With Nasal Polyps
The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps
This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of CM310 in patients with CRSwNP.
- Trial name
- NCT05131464
- Testing
- CM310
- Where
- 3 sites in China
- Volunteers
- 46 people
- Sponsor
- Keymed Biosciences Co.Ltd
Chronic Rhinosinusitis With Nasal Polyps
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
EFC18418 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 3 study with 3 treatment groups.
- Trial name
- CEREN-1 (NCT06834347)
- Testing
- Itepekimab (SAR440340), Mometasone furoate nasal spray (MFNS)
- Where
- 121 sites in United States, Argentina and 19 more
- Volunteers
- 231 people
- Sponsor
- Sanofi